Serum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy: Systematic review and meta-analysis

Mohamed E. Awad, Christina Sun, Joshua Jernigan, Mohammed Elsayed Elsalanty

Research output: Contribution to journalReview article

Abstract

Background: The authors’ aim in this systematic review was to evaluate the validity of using preoperative serum C-terminal cross-linking telopeptide (CTX) levels as a predictive factor of increased risk of developing medication-related osteonecrosis of the jaw (MRONJ) in patients receiving bisphosphonate (BP) therapy who underwent invasive dental procedures. Types of Studies Reviewed: The authors searched PubMed, MEDLINE, and Web of Science and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and the Cochrane Handbook for Systematic Reviews of Interventions. The authors conducted a meta-analysis on the risk ratio. The authors used the methodological index for nonrandomized studies and Quality Appraisal of Reliability Studies checklist to assess quality. Results: The authors included 18 clinical trials involving 2,301 patients. Most patients received alendronate or risedronate for an average of 62.14 months. The average serum CTX level in patients who received BP before surgery was 198.25 picograms per milliliter. Meta-analysis results showed that the cutoff in CTX level (150 pg/mL) was not predictive of MRONJ risk. The sensitivity of CTX values lower than 150 pg/mL was 34.26%, and the specificity was 77.08%. Conclusions and Practical Implications: The use of CTX levels to diagnose MRONJ risk after dental procedures in patients receiving BP is not justified. The cutoff of 150 pg/mL in serum CTX levels is not predictive of MRONJ. Further studies are needed to develop other reliable biomarkers.

Original languageEnglish (US)
Pages (from-to)664-675.e8
JournalJournal of the American Dental Association
Volume150
Issue number8
DOIs
StatePublished - Aug 1 2019

Fingerprint

Osteonecrosis
Diphosphonates
Meta-Analysis
Jaw
Biomarkers
Serum
Tooth
Therapeutics
Alendronate
Checklist
PubMed
MEDLINE
Odds Ratio
Clinical Trials
Guidelines

Keywords

  • Bisphosphonate-associated osteonecrosis
  • alveolar bone
  • bone
  • clinical protocols

ASJC Scopus subject areas

  • Dentistry(all)

Cite this

@article{0a07e7e616a0402ea52e920b8cf4b22b,
title = "Serum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy: Systematic review and meta-analysis",
abstract = "Background: The authors’ aim in this systematic review was to evaluate the validity of using preoperative serum C-terminal cross-linking telopeptide (CTX) levels as a predictive factor of increased risk of developing medication-related osteonecrosis of the jaw (MRONJ) in patients receiving bisphosphonate (BP) therapy who underwent invasive dental procedures. Types of Studies Reviewed: The authors searched PubMed, MEDLINE, and Web of Science and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and the Cochrane Handbook for Systematic Reviews of Interventions. The authors conducted a meta-analysis on the risk ratio. The authors used the methodological index for nonrandomized studies and Quality Appraisal of Reliability Studies checklist to assess quality. Results: The authors included 18 clinical trials involving 2,301 patients. Most patients received alendronate or risedronate for an average of 62.14 months. The average serum CTX level in patients who received BP before surgery was 198.25 picograms per milliliter. Meta-analysis results showed that the cutoff in CTX level (150 pg/mL) was not predictive of MRONJ risk. The sensitivity of CTX values lower than 150 pg/mL was 34.26{\%}, and the specificity was 77.08{\%}. Conclusions and Practical Implications: The use of CTX levels to diagnose MRONJ risk after dental procedures in patients receiving BP is not justified. The cutoff of 150 pg/mL in serum CTX levels is not predictive of MRONJ. Further studies are needed to develop other reliable biomarkers.",
keywords = "Bisphosphonate-associated osteonecrosis, alveolar bone, bone, clinical protocols",
author = "Awad, {Mohamed E.} and Christina Sun and Joshua Jernigan and Elsalanty, {Mohammed Elsayed}",
year = "2019",
month = "8",
day = "1",
doi = "10.1016/j.adaj.2019.03.006",
language = "English (US)",
volume = "150",
pages = "664--675.e8",
journal = "Journal of the American Dental Association",
issn = "0002-8177",
publisher = "American Dental Association",
number = "8",

}

TY - JOUR

T1 - Serum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy

T2 - Systematic review and meta-analysis

AU - Awad, Mohamed E.

AU - Sun, Christina

AU - Jernigan, Joshua

AU - Elsalanty, Mohammed Elsayed

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Background: The authors’ aim in this systematic review was to evaluate the validity of using preoperative serum C-terminal cross-linking telopeptide (CTX) levels as a predictive factor of increased risk of developing medication-related osteonecrosis of the jaw (MRONJ) in patients receiving bisphosphonate (BP) therapy who underwent invasive dental procedures. Types of Studies Reviewed: The authors searched PubMed, MEDLINE, and Web of Science and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and the Cochrane Handbook for Systematic Reviews of Interventions. The authors conducted a meta-analysis on the risk ratio. The authors used the methodological index for nonrandomized studies and Quality Appraisal of Reliability Studies checklist to assess quality. Results: The authors included 18 clinical trials involving 2,301 patients. Most patients received alendronate or risedronate for an average of 62.14 months. The average serum CTX level in patients who received BP before surgery was 198.25 picograms per milliliter. Meta-analysis results showed that the cutoff in CTX level (150 pg/mL) was not predictive of MRONJ risk. The sensitivity of CTX values lower than 150 pg/mL was 34.26%, and the specificity was 77.08%. Conclusions and Practical Implications: The use of CTX levels to diagnose MRONJ risk after dental procedures in patients receiving BP is not justified. The cutoff of 150 pg/mL in serum CTX levels is not predictive of MRONJ. Further studies are needed to develop other reliable biomarkers.

AB - Background: The authors’ aim in this systematic review was to evaluate the validity of using preoperative serum C-terminal cross-linking telopeptide (CTX) levels as a predictive factor of increased risk of developing medication-related osteonecrosis of the jaw (MRONJ) in patients receiving bisphosphonate (BP) therapy who underwent invasive dental procedures. Types of Studies Reviewed: The authors searched PubMed, MEDLINE, and Web of Science and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and the Cochrane Handbook for Systematic Reviews of Interventions. The authors conducted a meta-analysis on the risk ratio. The authors used the methodological index for nonrandomized studies and Quality Appraisal of Reliability Studies checklist to assess quality. Results: The authors included 18 clinical trials involving 2,301 patients. Most patients received alendronate or risedronate for an average of 62.14 months. The average serum CTX level in patients who received BP before surgery was 198.25 picograms per milliliter. Meta-analysis results showed that the cutoff in CTX level (150 pg/mL) was not predictive of MRONJ risk. The sensitivity of CTX values lower than 150 pg/mL was 34.26%, and the specificity was 77.08%. Conclusions and Practical Implications: The use of CTX levels to diagnose MRONJ risk after dental procedures in patients receiving BP is not justified. The cutoff of 150 pg/mL in serum CTX levels is not predictive of MRONJ. Further studies are needed to develop other reliable biomarkers.

KW - Bisphosphonate-associated osteonecrosis

KW - alveolar bone

KW - bone

KW - clinical protocols

UR - http://www.scopus.com/inward/record.url?scp=85067936239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067936239&partnerID=8YFLogxK

U2 - 10.1016/j.adaj.2019.03.006

DO - 10.1016/j.adaj.2019.03.006

M3 - Review article

AN - SCOPUS:85067936239

VL - 150

SP - 664-675.e8

JO - Journal of the American Dental Association

JF - Journal of the American Dental Association

SN - 0002-8177

IS - 8

ER -